Previous 10 | Next 10 |
Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an...
Nature delivers some spectacular special situations from time to time. These provide experiences rarely encountered. We are enriched by finding them. Special situation investing is a class of opportunities that arises from a departure of the normal course of business and trading. Mergers, acqu...
With Starboard Value lurking around acquirer Bristol-Myers Squibb ( BMY ), Celgene ( CELG ) shareholders are left with a minor risk that the deal gets blocked. The good news is that the company doesn't need Bristol-Myers. The bad news is that the initial reaction to a blocked deal is the s...
Now that January is in the books, it’s time for my monthly portfolio review. January was a great month for the market, yet a relatively tame month for my management. It seemed like I was buying stock left and right during December. This behavior followed through into early January, but ...
Background When I first commented on Roche ( RHHBY ), the world's largest biotech company and also the world's largest diagnostic instrument company, in February 2017, the ADRs had been around $31. Basic information about the ADRs can be found at this Roche web page . RHHBY has met my bas...
Last week I wrote about the Celgene ( CELG )/Bristol-Myers Squibb ( BMY ) deal spread. I noted that the double-digit deal spread is attractive and I have invested as such. News of Starboard's Stake Over the weekend, it was reported that Starboard has taken a stake in BMY. At the time o...
Recent Company Background: bluebird bio ( BLUE ) is one of the larger ($7.4B market cap) pure biotechs focused on the cell/gene therapy and CAR-T space. They have recently been making the rounds in the news regarding their exciting developments . Although they are a diverse biotech, looking...
NEW YORK , Feb. 5, 2019 /PRNewswire/ -- Lyfebulb, a chronic disease-focused, patient-empowerment platform that connects patients with industry and investors to support user-driven innovation, and Celgene Corporation (NASDAQ: CELG) announced the Lyfebulb-Celgene 2019 "Addressing Unmet...
A Phase 3 clinical trial, ICARIA-MM , evaluating Sanofi's (NASDAQ: SNY ) isatuximab in patients with relapsed/refractory multiple myeloma (MM) met the primary endpoint of progression-free survival (PFS). More news on: Sanofi, Celgene Corporation, Healthcare stocks news, Read more .....
"A cynic is a man who, when he smells flowers, looks around for a coffin." - H.L. Mencken Stocks ended January on a high note with the major indices up just under one and half percent last week. It was the best start to a New Year since 1987 for investors after a dismal fourth quarter. T...
News, Short Squeeze, Breakout and More Instantly...
Celgene Corporation Company Name:
CELG Stock Symbol:
NASDAQ Market:
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...
What coronavirus? Amgen 's (NASDAQ: AMGN) latest set of quarterly figures, delivered Tuesday, showed growth in the company's fundamentals during a challenging time for companies across all economic sectors. The veteran biotech company booked revenue of nearly $6.21 billion in the second qu...
It's scary out there right now for investors, with wild market swings and a lot of negative news coming out of quarterly reports. There is one sector, however, that will survive and likely thrive despite the coronavirus pandemic shutdown -- healthcare. That said, investors shouldn't head for jus...